NasdaqCM:OTLKBiotechs
Outlook Therapeutics (OTLK) Is Up 60.7% After FDA Class 1 Review Acceptance For Lytenava
Outlook Therapeutics previously secured FDA acceptance of its resubmitted Biologics License Application for ONS-5010/Lytenava, following a successful appeal that confirmed substantial evidence of effectiveness and removed the requirement for new clinical trials.
The FDA’s Class 1 review with a roughly 60-day PDUFA timeline, combined with ongoing launches in Europe and the UK, places Lytenava at the center of Outlook Therapeutics’ path toward broader commercial reach.
We’ll now examine how...